Επικοινωνήστε μαζί μας

Για το περιεχόμενο

Για την πλοήγηση

210 6930521

Βιογραφικό


Νευρολόγος Μαρία Σταμέλου

ΣΤΑΜΕΛΟΥ ΜΑΡΙΑ
Επίκουρη καθηγήτρια Νευρολογίας Παν/μου Marburg, Γερμανία
Υπεύθυνη τμήματος Πάρκινσον και Κινητικών Διαταραχών Νοσοκομείου "ΥΓΕΙΑ"
Εξειδικευμένη στη Νόσο Πάρκινσον & άλλες Κινητικές Διαταραχές, UCL, Αγγλία
Πανεπιστημιακή Υπότροφος ΕΚΠΑ

Εκπαίδευση & Ακαδημαϊκοί Τίτλοι
  • 10/2010-02/2013 Eξειδίκευση στη νόσο Πάρκινσον και Κινητικές Διαταραχές (UCL, Sobell Dept. of Motor Neurosciences and Movement Disorders, Queen Square, London, UK)
  • 01/2005-10/2010 Ειδικότητα Νευρολογίας: Philipps-University, Marburg, Germany
  • 2005-2010 Ειδικά εξωτερικά ιατρεία για νόσο Πάρκινσον και Κινητικές Διαταραχές
  • 2005-2010 Ειδικά εξωτερικά ιατρεία για άτυπα παρκινσονικά σύνδρομα
  • 2009-2010 Ειδικά εξωτερικά ιατρεία για ενδομυϊκές ενέσεις συγκεκριμένης τοξίνης (http://www.hygeia.gr/Services/departments/department/731/kinitikon-diataraxon.html) σε δυστονίες, σπαστικότητα και υπεριδρωσία με ηλεκτρομυογραφικό έλεγχο (πιστοποίηση από την γερμανική εταιρεία ΒοΝΤ)
  • 2007-2009 Μονάδα εντατικής θεραπείας για νευρολογικές νόσους (εκπαίδευση σε επείγουσα ιατρική, διασωληνώσεις, τοποθέτηση κεντρικών γραμμών)
  • 2009-2010 Εκπαίδευση στην ηλεκτροφυσιολογία, ΕΜΓ, ΕΝΓ, προκλητά δυναμικά, ΕΕΓ
  • 2001-2002 Erasmus exchange programme: Πανεπιστήμιο Freiburg, Γερμανία
  • 1996-2002 MD, Πτυχίο Ιατρικής: Αριστοτέλειο Παν/μο Θεσσαλονίκης, Τμήμα ιατρικής


ΕΚΠΑΙΔΕΥΤΙΚΗ ΠΕΙΡΑ

  • Διδασκαλία σε προπτυχιακους και μεταπτυχιακους φοιτητες στο Παν/μο Marburg απο το 2005 εως σημερα
  • Διδασκαλία σε προπτυχιακους φοιτητες και ειδικευομενους στην Β’ Παν/κη Νευρολογική κλινική, Αττικό Νοσοκομείο απο το 2013
  • Ομιλήτριασε teaching courses του Intenational Movement Disorders Society
Διδακτορική Διατριβή
  • 01/2005 – 09/2009 PhD, Διδακτορικήδιατριβή “Coenzyme Q10 in progressive supranuclear palsy: a randomized, double-blind, placebo-controlled study” (PUM, Germany, «άρισταμεδιάκριση», summa cum laude)
Μέλος Εταιριών, Συντακτικής Επιτροπής Περιοδικών
  • Movement Disorders Journal (Assistant Editor), since Dec 2013
  • International Movement Disorders Society
  • Americal Academy of Neurology (AAN)
  • European Neurological Society/ European Federation of Neurological Society
  • Ελληνική Νευρολογική Εταιρεία
  • GermanParkinsonStudyGroup
  • German Association for Botulinum Toxin Therapy
  • German PSP Study Group
  • Frontiers in Movement Disorders (Editorial Board), since 2013

AD-HOC REVIEWER ΓΙΑ ΕΠΙΣΤΗΜΟΝΙΚΑ ΠΕΡΙΟΔΙΚΑ

  • Lancet Neurology
  • PLOS one
  • Cerebral Cortex
  • American Journal of Neuroradiology
  • Journal of Neurological Sciences
  • Neuroepidemiology
  • Journal of Neurology, Neurosurgery and Psychiatry
  • CNS & Neurological Disorders
  • Parkinsonism and Related Disorders
  • Movement Disorders Cinical Practice
  • Journal of Alzheimer disease
  • Clinical Genetics
  • Movement Disorders Journal
Επαγγελματική Προϋπηρεσία
  • Από το 2013 Β’ Παν/κη Νευρολογική κλινική, Αττικό Νοσοκομείο, ειδικά ιατρεία για Πάρκινσον και κινητικές διαταραχές
  • Από το 2013 ιδιωτικό ιατρείο Πάρκινσον και κινητικών διαταραχών
  • 2010-2013 Ειδικά ιατρεία για Πάρκινσον και κινητικές διαταραχές και ειδικά ιατρεία για ενδομυϊκές ενέσεις συγκεκριμένης τοξίνης (http://www.hygeia.gr/Services/departments/department/731/kinitikon-diataraxon.html) UCL, Queen Square, Αγγλία
  • 2005-2010 Ειδικότητα νευρολογίας Philipps-University, Μarburg, Γερμανία
  • 2003-2004 Αγροτική θητεία Νομαρχιακό Νοσοκομείο Κορίνθου
Κλινικό & Ερευνητικό Ενδιαφέρον
  • Νόσος Πάρκινσον
  • Άτυπα παρκινσονικά σύνδρομα (Προϊούσα Υπερπυρηνική Παράλυση, Ατροφία Πολλαπλών Συστημάτων, Φλοιοβασική Εκφύλιση)
  • Δυστονίες (πρωτοπαθείς και δευτεροπαθείς, αυχενική δυστονία, βλεφαρόσπασμος, Meige, σπασμός γραφέα κτλ)
  • Τρόμος
  • Τικς (Tourette’s σύνδρομο)
  • Χορεία (νόσος Huntington κτλ)
  • Μυόκλονος
  • Αταξία
  • Σύνδρομα stiff-person

Ερευνητικό ενδιαφέρον:

  • Κλινικές μελέτες στην Νόσο Πάρκινσον
  • Κλινικές μελέτες στην Προϊούσα Υπερπυρηνική Παράλυση (PSP)
  • Φαινοτυπικές και γενετικές μελέτες σε οικογενείς μορφές περίπλοκων κινητικών διαταραχών
  • Κλινικές μελέτες σε οικογενείς μορφές Πάρκινσον, κυρίως σε ασθενείς με μεταλλάξεις στο γονίδιο της α-σουνουκλείνης
Διακρίσεις & Βραβεία
  • 2009 ΒΡΑΒΕΙΟ του ιατρικού συλλόγου Hessen, Germany για την καλυτερη διδακτορική διατριβή στο κρατίδιο
  • 2009 ΒΡΑΒΕΙΟ του Πανεπιστημίου Philipps, Marburg για την καλύτερη διδακτορική διατριβή στην ιατρική το 2009
  • 2009 MLP – βραβείο για την καλύτερη διδακτορική διατριβή στην ιατρική 2009
  • 2010 Freundlich – Stiftung award for innovative therapies για “Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial”
  • 2011-2012 Scientific fellowship from the European Federation of Neurological Societies (EFNS)
Ομιλίες σε διεθνή συνέδρια (selected)
  • Atypical Parkinson Syndromes: Practical Therapy. 6th German Parkinson Congress, 2009, Marburg, Germany
  • Effects of coenzyme Q10 in progressive supranuclear palsy. 23. Greek neurology congress, May 2009,Thessaloniki, Greece
  • Differential Diagnosis of atypical parkinsonian conditions: British-Turkish Meeting, Queen Square, April 2012
  • Progressive supranuclear palsy: Treatment. Teaching Course, International Movement Disorders Congress,Dublin, Ireland, 2012
  • PSP diagnostics. 1st German PSP meeting, Munich, Germany, 2012
  • The spectrum of cranio-cervical dystonias,International Movement Disorders Congress, Sydney, Australia, 2013
  • Atypical parkinsonism : Summer school for Movement Disorders, MDS, London, July 2013
  • The differential diagnosis of vascular parkinsonism with Parkinson’s disease and atypical parkinsonism, International Congress of Vascular Dementia, Athens, 2013
  • PSP treatment: 18th International Movement Disorders Society Congress, Stockholm, June, 2014
  • Other hereditary parkinsonian syndromes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
  • Genetic PSP-, CBD-, MSA- look alikes: Genetics of Parkinson's disease and other parkinsonian syndromes in clinical practice, International Movement Disorders Society, Athens, 3-4th October, 2014 (Course Director)
  • PSP-look alikes: 50 Years of progressive supranuclear palsy; MDS, Munich, Germany, 9-10th October 2014
  • Update on PSP: Annual Parkinson Meeting; Ancona, Italy, 16-17th October 2014
  • The non-motor syndrome of dystonia: International Congress on Non-motor dysfunction in Parkinson's disease and related disorders (NMDPD), Nice, France, 4-7th December 2014
  • Movement Disorders in the Media. 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015
  • Invited expert in Video Challenge, 19th International Movement Disorders Society Congress, San Diego, CA, USA June, 2015 
  • Update on atypical parkinsonism, Deutsche Gesselschaft für Neurologie (DGN) Kongress, Düsseldorf, October, 2015
  • Interventions in PSP: World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
  • Unusual Movement Disorders, Video Session. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
  • PSP subtypes and phenotypes. World congress on Parkinson’s disease and related disorders: Milan, Italy, 6-9 December 2015
Βιβλία
  • Stamelou M, Edwards MJ, Quinn N, Bhatia KP: Parkinson’s disease and other movement disorders, Oxford Specialists Handbooks in neurology, Oxford University Press, in preparation
  • Stamelou M, Erro R, Bhatia K: Case studies in Movement Disorders, Cambridge University Press, in preparation
  • Christ H, Stamelou M, Höglinger GU. Die Medizinischen Grundlagen der Progressiven Supranukleären Blickparese. In: Wagner S, Kotz S (Hrg.). Progressive Supranukleäre Blickparese (PSP) – Sprechen, Sprache, Kommunikation. Leipzig 2009
  • Höglinger GU, Oertel WH, Stamelou M. Progressive Supranukleäre Blickparese: in Parkinson-Syndrome und andere Bewegungsstörungen-Oertel, Deuschl, Poewe. Thieme Verlag, 2012 p:138-151
  • Höglinger GU, Oertel WH , Stamelou M. Kortikobasale Degeneration: in Parkinson-Syndrome und andere Bewegungsstörungen -Oertel, Deuschl, Poewe. Thieme Verlag, 2012 p: 151-159
  • Bhatia KP, Stamelou M, Bressman S. Dystonia: and overview, Oxford Textbook of Movement Disorders, Oxford University Press, 2013
  • Stamelou M, Bhatia KP. Dementia in Parkinson’s disease and atypical parkinsonism, In Dementia in Movement Disorders, Merello, Springer, in press
  • Erro R, Stamelou M, Bhatia KP. Paroxysmal movement disorders In Parkinson’s Disease and Movement Disorders. Jankovic, Tolosa, Wolters Kluwer Health —Lippincott Williams & Wilkins
  • Βιβλίο Μαρίας Δ. Σταμέλου: https://global.oup.com/academic/product/parkinsons-disease-and-other-movement-disorders-9780198705062?cc=gr&lang=en&
Δημοσιεύσεις

ΣΕ ΔΙΕΘΝΗ ΠΕΡΙΟΔΙΚΑ

  • The clinical and genetic heterogeneity of paroxysmal dyskinesias.Gardiner AR, Jaffer F, Dale RC, Labrum R, Erro R, Meyer E, Xiromerisiou G, Stamelou M, Walker M, Kullmann D, Warner T, Jarman P, Hanna M, Kurian MA, Bhatia KP, Houlden H.Brain. 2015 Dec;138(Pt 12):3567-80. 
  • From a single nucleotide polymorphism to tau pathology: Appoptosin is the missing link.Respondek G, Höglinger GU, Stamelou M.Mov Disord. 2015 Nov 14.
  • Interventions in progressive supranuclear palsy. Koros C, Stamelou M.Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S93-5.
  • Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.Nalls
    MA, McLean CY, Rick J, et al ; Parkinson's Disease Biomarkers Program and
    Parkinson's Progression Marker Initiative investigators.Lancet Neurol. 2015 Oct;14(10):1002-9.
  • The role of cerebellum in patients with late onset cervical/segmental dystonia?-Evidence from the clinic.Batla A, Sánchez MC, Erro R, Ganos C, Stamelou M, Balint B, Brugger F, Antelmi E, Bhatia KP.Parkinsonism Relat Disord. 2015 Sep 5. pii: S1353-8020(15)00388-0. 
  • Multiple system atrophy-mimicking conditions: Diagnostic challenges.Kim HJ, Stamelou M, Jeon B.Parkinsonism Relat Disord. 2015 Sep 5. pii: S1353-8020(15)00378-8.
  • The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.Stamelou M, Diehl-Schmid J, Hapfelmeier A, Kontaxopoulou D, Stefanis L, Oertel WH, Bhatia KP, Papageorgiou SG, Höglinger GU.Parkinsonism Relat Disord. 2015 Aug 11. pii: S1353-8020(15)00338-7. doi: 10.1016/
  • Reward Pays the Cost of Noise Reduction in Motor and Cognitive Control. Manohar SG, Chong TT, Apps MA, Batla A, Stamelou M, Jarman PR, Bhatia KP, Husain M.Curr Biol. 2015 Jun 29;25(13):1707-16.
  • ADCY5 mutations are another cause of benign hereditary chorea. Mencacci NE, Erro R, Wiethoff S, Hersheson J, Ryten M, Balint B, Ganos C, Stamelou M, Quinn N, Houlden H, Wood NW, Bhatia KP. Neurology. 2015 Jul 7;85(1):80-8.
  • What do patients with scans without evidence of dopaminergic deficit (SWEDD) have? New evidence and continuing controversies.Erro R, Schneider SA, Stamelou M, Quinn NP, Bhatia KP. J Neurol Neurosurg Psychiatry. 2015 May 19. [Epub ahead of print]
  • Brain energy metabolism in early MSA-P: A phosphorus and proton magnetic resonance spectroscopy study.Stamelou M, Pilatus U, Reuss A, Respondek G, Knake S, Oertel WH, Höglinger GU.Parkinsonism Relat Disord. 2015 Mar 12.
  • Mutations in HPCA Cause Autosomal-Recessive Primary Isolated Dystonia.Charlesworth G, Angelova PR, Bartolomé-Robledo F, Ryten M, Trabzuni D, Stamelou M, Abramov AY, Bhatia KP, Wood NW.Am J Hum Genet. 2015 Apr 2;96(4):657-65. doi: 10.1016/j.ajhg.2015.02.007. Epub 2015 Mar 19. 
  • H-ABC syndrome and DYT4: Variable expressivity or pleiotropy of TUBB4 mutations? Erro R, Hersheson J, Ganos C, Mencacci NE, Stamelou M, et al. .Mov Disord. 2014 Dec 27. doi: 10.1002/mds.26129
  • Atypical Parkinsonism: Diagnosis and Treatment. Stamelou M, Bhatia KP.Neurol Clin. 2015 Feb;33(1):39-56. doi: 1016/j.ncl.2014.09.012. Review. 
  • The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases. Respondek G*, Stamelou
    M,*
    et al; for the Movement Disorder  Society-endorsed PSP Study Group.Mov Disord. 2014 Nov 5. doi: 10.1002/mds.26054. *equal contribution
  • Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study.Batla A, Erro R, Stamelou M, et al.Mov Disord. 2014 Oct 28. doi: 10.1002/mds.26018. [Epub ahead of print] 
  • The entity of parkinsonism and associated lipomatosis.Stamelou M, Sheerin UM, Wood N, Bhatia KP. Neurology. 2014 Oct 1 
  • Clinical relevance of serum antibodies to extracellular N-methyl-d-aspartate receptor epitopes.Zandi MS, Paterson RW, Ellul MA, Jacobson L, Al-Diwani A, Jones JL, Cox AL, Lennox B, Stamelou M, Bhatia KP, Schott JM, Coles AJ, Kullmann DM, Vincent A.J Neurol Neurosurg Psychiatry. 2014 Sep 22
  • All in the blink of an eye: new insight into cerebellar and brainstem function in DYT1 and DYT6 dystonia.Sadnicka A, Teo JT, Kojovic M, Pareés I, Saifee TA, Kassavetis P, Schwingenschuh P, Katschnig-Winter P, Stamelou M, Mencacci NE, Rothwell JC, Edwards MJ, Bhatia KP. Eur J Neurol. 2014 Jul 18.
  • Parkinson's disease in GTP cyclohydrolase 1 mutation carriers.Mencacci NE, Isaias IU, Reich MM, Ganos C, Plagnol V, Polke JM, Bras J, Hersheson J, Stamelou
    M,
    et al; International Parkinson’s Disease Genomics Consortium and UCL-exomes consortium.Brain. 2014 Sep;137(Pt 9):2480-92.
  • The expanding universe of disorders of the basal ganglia.Obeso JA, Rodriguez-Oroz MC, Stamelou M, Bhatia KP, Burn DJ.Lancet. 2014 Aug 9;384(9942):523-31.
  • Facial tremor in dystonia.Erro R, Stamelou M, Saifee TA, Ganos C, Antelmi E, Balint B, Cordivari C, Bhatia KP.Parkinsonism Relat Disord. 2014 Aug;20(8):924-5. doi: 10.1016/j.parkreldis.2014.04.029.
  • Commentary.Stamelou M.Mov Disord. 2014 Mar;29(3):310. doi: 10.1002/mds.25848. No abstract available.
  • Susceptibility-weighted imaging changes suggesting brain iron accumulation in Huntington's  disease: an epiphenomenon which causes diagnostic difficulty.Macerollo A, Perry R, Stamelou M, Batla A, Mazumder AA, Adams ME, Bhatia KP.Eur J Neurol. 2014 Feb;21(2):e16-7.
  • ALS2 mutations: juvenile amyotrophic lateral sclerosis and generalized dystonia.Sheerin UM, Schneider SA, Carr L, Deuschl G, Hopfner F, Stamelou M, Wood NW, Bhatia KP.Neurology. 2014 Mar 25;82(12):1065-7.
  • A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy.Tolosa E, Litvan I, Höglinger GU, Burn D, Lees A, Andrés MV, Gómez-Carrillo B, León T, Del Ser T; TAUROS Investigators.Mov Disord. 2014 Apr;29(4):470-8. doi: 10.1002/mds.25824.
  • Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.Höglinger GU, Huppertz HJ, Wagenpfeil S, Andrés MV, Belloch V, León T, Del Ser T; TAUROS MRI Investigators.Mov Disord. 2014 Apr;29(4):479-87. doi: 10.1002/mds.25815.
  • The phenotypic spectrum of DYT24 due to ANO3 mutations.Stamelou M, Charlesworth G, Cordivari C, Schneider SA, Kägi G, Sheerin UM, Rubio-Agusti I, Batla A, Houlden H, Wood NW, Bhatia KP. Mov Disord. 2014 Jun;29(7):928-34. doi: 10.1002/mds.25802.
  • Genome wide association study in cervical dystonia demonstrates possible association with sodium leak channel. Mok KY, Schneider SA, Trabzuni D, Stamelou M, Edwards M, Kasperaviciute D, Pickering-Brown S, Silverdale M, Hardy J, Bhatia KP.Mov Disord. 2013 Nov 13. doi: 10.1002/mds.25732. 
  • Psychogenic paroxysmal movement disorders - Clinical features and diagnostic clues.Ganos C, Aguirregomozcorta M, Batla A, Stamelou M, Schwingenschuh P, Münchau A, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Sep 19.
  • Ataxia telangiectasia presenting as dopa-responsive cervical dystonia.Charlesworth G, Mohire MD, Schneider SA, Stamelou M, Wood NW, Bhatia KP.Neurology. 2013 Sep 24;81(13):1148-51.
  • Atypical parkinsonism: an update.Stamelou M, Hoeglinger GU.Curr Opin Neurol. 2013 Aug;26(4):401-5.
  • MSA-QoL: disease-specific questionnaire to assess health-related quality of life in multiple system atrophy: validation of the German translation.Krismer F, Duerr S, Minnerop M, Klockgether T, Stamelou M, Eggert KM, Oertel WH, Schrag A, Poewe W, Wenning GK.Nervenarzt. 2013 Jun;84(6):709-14.
  • Markedly asymmetric presentation in multiple system atrophy.Batla A, Stamelou M, Mensikova K, Kaiserova M, Tuckova L, Kanovsky P, Quinn N, Bhatia KP.Parkinsonism Relat Disord. 2013 Oct;19(10):901-5.
  • Dystonic opisthotonus: A "red flag" for neurodegeneration with brain iron accumulation syndromes?Stamelou M, Lai SC, Aggarwal A, Schneider SA, Houlden H, Yeh TH, Batla A, Lu CS, Bhatt M, Bhatia KP.Mov Disord. 2013 Sep;28(10):1325-9.
  • "Atypical" atypical parkinsonism: new genetic conditions presenting with features of progressive supranuclear palsy, corticobasal degeneration, or multiple system atrophy-a diagnostic guide.Stamelou M, Quinn NP, Bhatia KP.Mov Disord. 2013 Aug;28(9):1184-99.
  • Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study.Stamelou M, Christodoulou C, Stefanis L.Mov Disord. 2013 May;28(5):689.
  • Familial psychogenic movement disorders.Stamelou M, Cossu G, Edwards MJ, Murgia D, Pareés I, Melis M, Bhatia KP.Mov Disord. 2013 Aug;28(9):1295-8. doi: 10.1002/mds.25463.
  • Commentary for "Slowing of saccadic eye movements in sporadic Creutzfeldt-Jakob disease".Stamelou M. Mov Disord. 2013 Mar;28(3):293-4.
  • Tremulous cervical dystonia is likely to be familial: clinical characteristics of a large cohort.Rubio-Agusti I, Pareés I, Kojovic M, Stamelou M, Saifee TA, Charlesworth G, Sheerin UM, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Jun;19(6):634-8.
  • Progressive ataxia and palatal tremor associated with dense pontine calcification: A unique case.Stamelou M, Adams M, Davagnanam I, Batla A, Sheerin U, Talbot K, Bhatia KP. Mov Disord. 2013 Jul;28(8):1155-7.
  • Functional movement disorders are not uncommon in the elderly.Batla A, Stamelou M, Edwards MJ, Pareés I, Saifee TA, Fox Z, Bhatia KP.Mov Disord. 2013 Apr;28(4):540-3.
  • Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.Batla A, Stamelou M, Mencacci N, Schapira AH, Bhatia KP.Mov Disord. 2013 Jul;28(8):1159-60.
  • Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease.Marx S, Respondek G, Stamelou M, Dowiasch S, Stoll J, Bremmer F, Oertel WH, Höglinger GU, Einhäuser W.Front Behav Neurosci. 2012;6:88.
  • Mutations in ANO3 cause dominant craniocervical dystonia: ion channel implicated in pathogenesis.Charlesworth G, Plagnol V, Holmström KM, Bras J, Sheerin UM, Preza E, Rubio-Agusti I, Ryten M, Schneider SA, Stamelou M, Trabzuni D, Abramov AY, Bhatia KP, Wood NW.Am J Hum Genet. 2012 Dec 7;91(6):1041-50.
  • Patients with rest-tremor and scans with ipsilateral dopaminergic deficit.Aguirregomozcorta M*, Stamelou M,* Antonini A, Schwingenschuh P, Prvulovich L, Edwards MJ, Dickson JC, Bhatia KP.J Neurol. 2013 Apr;260(4):1132-5. *equal contribution
  • Migraine with aura as the predominant phenotype in a family with a PRRT2 mutation.Sheerin UM, Stamelou M, Charlesworth G, Shiner T, Spacey S, Valente EM, Wood NW, Bhatia KP.J Neurol. 2013 Feb;260(2):656-60.
  • PRRT2 gene mutations: from paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine.Gardiner AR, Bhatia KP, Stamelou M, Dale RC, Kurian MA, Schneider SA, Wali GM, Counihan T, Schapira AH, Spacey SD, Valente EM, Silveira-Moriyama L, Teive HA, Raskin S, Sander JW, Lees A, Warner T, Kullmann DM, Wood NW, Hanna M, Houlden H.Neurology. 2012 Nov 20;79(21):2115-21.
  • The differential diagnosis of Huntington's disease-like syndromes: 'red flags' for the clinician.Martino D, Stamelou M, Bhatia KP.J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):650-6.
  • Dystonia with brain manganese accumulation resulting from SLC30A10 mutations: a new treatable disorder.Stamelou M, Tuschl K, Chong WK, Burroughs AK, Mills PB, Bhatia KP, Clayton PT.Mov Disord. 2012 Sep 1;27(10):1317-22.
  • THAP1 mutations and dystonia phenotypes: genotype phenotype correlations.Xiromerisiou G, Houlden H, Scarmeas N, Stamelou M, Kara E, Hardy J, Lees AJ, Korlipara P, Limousin P, Paudel R, Hadjigeorgiou GM, Bhatia KP.Mov Disord. 2012 Sep 1;27(10):1290-4.
  • Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency.Stamelou M, Mencacci NE, Cordivari C, Batla A, Wood NW, Houlden H, Hardy J, Bhatia KP.Neurology. 2012 Jul 31;79(5):435-41.
  • A new treatable genetic disorder of manganese metabolism causing dystonia-parkinsonism and cirrhosis: the "new" Wilson's disease?Stamelou M, Bhatia KP.Mov Disord. 2012 Jul;27(8):962.
  • Late onset rest-tremor in DYT1 dystonia.Stamelou M, Edwards MJ, Bhatia KP.Parkinsonism Relat Disord. 2013 Jan;19(1):136-7.
  • The distinct movement disorder in anti-NMDA receptor encephalitis may be related to Status Dissociatus: a hypothesis. Stamelou M, Plazzi G, Lugaresi E, Edwards MJ, Bhatia KP.Mov Disord. 2012 Sep 15;27(11):1360-3.
  • Dystonia in corticobasal degeneration: a review of the literature on 404 pathologically proven cases.Stamelou M, Alonso-Canovas A, Bhatia KP.Mov Disord. 2012 May;27(6):696-702.
  • Psychogenic palatal tremor may be underrecognized: reappraisal of a large series of cases.Stamelou M, Saifee TA, Edwards MJ, Bhatia KP.Mov Disord. 2012 Aug;27(9):1164-8.
  • Treatment of focal dystonia.Batla A, Stamelou M, Bhatia KP.Curr Treat Options Neurol. 2012 Jun;14(3):213-29.
  • Patients with idiopathic rapid-eye-movement sleep behavior disorder show normal gastric motility assessed by the 13C-octanoate breath test.Unger MM, Möller JC, Mankel K, Schmittinger K, Eggert KM, Stamelou M, Stiasny-Kolster K, Bohne K, Bodden M, Mayer G, Oertel WH, Tebbe JJ.Mov Disord. 2011 Dec;26(14):2559-63.
  • Clinical pain and experimental pain sensitivity in progressive supranuclear palsy.Stamelou M, Dohmann H, Brebermann J, Boura E, Oertel WH, Höglinger G, Möller JC, Mylius V.Parkinsonism Relat Disord. 2012 Jun;18(5):606-8.
  • Movement disorders on YouTube--caveat spectator.Stamelou M, Edwards MJ, Espay AJ, Fung VS, Hallett M, Lang AE, Tijssen MA, Bhatia KP.N Engl J Med. 2011 Sep 22;365(12):1160-1.
  • The non-motor syndrome of primary dystonia: clinical and pathophysiological implications.Stamelou M, Edwards MJ, Hallett M, Bhatia KP.Brain. 2012 Jun;135(Pt 6):1668-81.
  • Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy.Höglinger GU, Melhem NM, Dickson DW, Sleiman PM, Wang LS, Klei L, Rademakers R, de Silva R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI, Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P; PSP Genetics Study Group, et al .Nat Genet. 2011 Jun 19;43(7):699-705.
  • Ability to cycle despite severe freezing of gait in atypical parkinsonism in Fahr's syndrome.Stamelou M, Kojovic M, Edwards MJ, Bhatia KP.Mov Disord. 2011 Sep;26(11):2141-2.
  • Health-related quality of life in multiple system atrophy and progressive supranuclear palsy.Winter Y, Spottke AE, Stamelou M, Cabanel N, Eggert K, Höglinger GU, Sixel-Doering F, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R.Neurodegener Dis. 2011;8(6):438-46.
  • Characteristic constant groaning in late stage progressive supranuclear palsy: a case report.Stamelou M, Rubio-Agusti I, Quinn N, Bhatia K.Parkinsonism Relat Disord. 2011 Aug;17(7):575-6.
  • AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B.Mov Disord. 2011 Jun;26(7):1243-50.
  • Cost-of-illness in multiple system atrophy and progressive supranuclear palsy.Winter Y, Stamelou M, Cabanel N, Sixel-Döring F, Eggert K, Höglinger GU, Herting B, Klockgether T, Reichmann H, Oertel WH, Dodel R, Spottke AE.J Neurol. 2011 Oct;258(10):1827-34. 
  • Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes.Stamelou M, Christ H, Reuss A, Oertel W, Höglinger G.Mov Disord. 2011 Apr;26(5):901-5.
  • Targeting the orexin system: a new approach for treating insomnia.Arias-Carrión O, Stamelou M.CNS Neurol Disord Drug Targets. 2010 Dec;9(6):667.
  • Magnetic resonance imaging in progressive supranuclear palsy.Stamelou M, Knake S, Oertel WH, Höglinger GU.J Neurol. 2011 Apr;258(4):549-58.
  • Dopaminergic reward system: a short integrative review.Arias-Carrión O, Stamelou M, Murillo-Rodríguez E, Menéndez-González M, Pöppel E.Int Arch Med. 2010 Oct 6;3:24.
  • Rational therapeutic approaches to progressive supranuclear palsy.Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU.Brain. 2010 Jun;133(Pt 6):1578-90.
  • In vivo demonstration of microstructural brain pathology in progressive supranuclear palsy: a DTI study using TBSS.Knake S, Belke M, Menzler K, Pilatus U, Eggert KM, Oertel WH, Stamelou M,* Höglinger GU*.Mov Disord. 2010 Jul 15;25(9):1232-8. *equal contribution
  • Nigrostriatal upregulation of 5-HT2A receptors correlates with motor dysfunction in progressive supranuclear palsy.Stamelou M, Matusch A, Elmenhorst D, Hurlemann R, Eggert KM, Zilles K, Oertel WH, Höglinger GU, Bauer A.Mov Disord. 2009 Jun 15;24(8):1170-5.
  • In vivo evidence for cerebral depletion in high-energy phosphates in progressive supranuclear palsy.Stamelou M, Pilatus U, Reuss A, Magerkurth J, Eggert KM, Knake S, Ruberg M, Schade-Brittinger C, Oertel WH, Höglinger GU.J Cereb Blood Flow Metab. 2009 Apr;29(4):861-70.
  • Combined 1H and 31P MR spectroscopic imaging: impaired energy metabolism in severe carotid stenosis and changes upon treatment.Hattingen E, Lanfermann H, Menon S, Neumann-Haefelin T, de Rochement RD,Stamelou M, Höglinger GU, Magerkurth J, Pilatus U.MAGMA. 2009 Feb;22(1):43-52.
  • [Atypical Parkinson syndromes].Strzelczyk A, Möller JC, Stamelou M, Matusch A, Oertel WH.Nervenarzt. 2008 Oct;79(10):1203-20
  • Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.Eggert K, Schrader C, Hahn M, Stamelou M, Rüssmann A, Dengler R, Oertel W, Odin P.Clin Neuropharmacol. 2008 May-Jun;31(3):151-66.
  • Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial.Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, Krisp A, Menke T, Schade-Brittinger C, Oertel WH, Höglinger GU.Mov Disord. 2008 May 15;23(7):942-9.